
Broncus Holding Corporation
2216.HKHKSEHealthcareMedical - Devices
Latest quote
HK$0.645
+HK$0.01 · +1.57%
2216.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteBroncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Hong Xu
- Listed since
- Sep 24, 2021
- Employees
- 191
Market position
52-week range
Current HK$0.645
- Open
- HK$0.645
- Previous close
- HK$0.635
- Volume
- 202.5K
- 0.41× average
- Average volume
- 498.53K
- Average daily volume
- Market cap
- 339.64M HKD
- Beta
- 1.19
- Market reference 1
- 50-day average
- HK$0.6678
- -3.41% below average
- 200-day average
- HK$1.462
- -55.88% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -2.22×
- P/B (TTM)
- 0.27×
- P/S (TTM)
- 248.67×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -1585.06%
- Operating margin
- -14017.85%
- Net margin
- -10273.01%
Financial health
- Debt / equity
- 0×
- Altman Z-score
- -0.24
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 174K USD | 8.13M USD | 10.26M USD | 9.41M USD | 10.89M USD |
| Cost of goods sold | 1.09M USD | 1.99M USD | 3.03M USD | 2.1M USD | 2.15M USD |
| Gross profit | −917K USD | 6.14M USD | 7.23M USD | 7.32M USD | 8.74M USD |
| Research and development | 7.77M USD | 11.47M USD | 20.15M USD | 19.17M USD | 16.76M USD |
| Selling, general, and administrative | 15.7M USD | 15.76M USD | 20.42M USD | 20.42M USD | 31.25M USD |
| Operating expenses | 23.47M USD | 28.63M USD | 40.45M USD | 40.02M USD | 46.17M USD |
| Interest income | 5.49M USD | 6.53M USD | 6.04M USD | 2.63M USD | 161K USD |
| Interest expense | 4.01K USD | 84K USD | 163K USD | 98K USD | 170K USD |
| Depreciation and amortization | 1.71M USD | 2.12M USD | 2.87M USD | 2.13M USD | 2.69M USD |
| Operating income | −24.39M USD | −22.49M USD | −33.22M USD | −32.71M USD | −39.85M USD |
| Net income | −17.88M USD | −15.3M USD | −28.09M USD | −28.04M USD | −236.18M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 20%
- 1 beat, 2 misses, 2 met estimates
- Average EPS surprise
- -83.11%
- 5 comparable reports
- Latest EPS result
- -0.16
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
2216.HK peers
Continue in GoAI
Research 2216.HKresearch.disclaimer





